Oncology Peer Review On-The-Go: BPCIA, 4-Letter Suffix Rule, & the Challenges of Prescribing Biosimilars


CancerNetwork®’s podcast hosted 2 experts to discuss the current state of biosimilar prescriptions and the need for change to improve the system overall.

In this episode of Oncology Peer Review On-The-Go, CancerNetwork® spoke with 2 experts on the topic of biosimilars, Howard Hochster, MD, FACP, associate director for Clinical Research at the Rutgers Cancer Institute of New Jersey as well as co-editor in chief of the journal ONCOLOGY®, and Distinguished Professor of Medicine at the Rutgers School of Medicine, and Michael Kane, RPh, BCOP, executive director of Oncology Pharmacy Services for RWJBarnabas Health and director of Pharmacy Services and the Research Pharmacy at the Rutgers Cancer Institute of New Jersey.

The episode dives into the history of biosimilars, including the Biologics Price Competition and Innovation Act (BPCIA) passed by the United States Congress in 2009 and the subsequent 4-letter suffix rule used to identify biologics products without confusion. The participants also analyzed some of the unintended consequences of these acts, and what they suggest for improving the current system.

Don’t forget to subscribe to the Oncology Peer Review On-The-Go podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Related Videos
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Lucio N. Gordan, MD, also discusses how increasing domestic manufacturing of chemotherapy may help in alleviating the ongoing shortages of carboplatin and cisplatin in the United States.
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, believes that national legislation can help to resolve the United States’ current dearth of cisplatin, as well as prevent future problems.
Using an AUC of 5 instead of an AUC of 6 can help to conserve cisplatin among patients with cancer, Kirollos Hanna, PharmD, BCPS, BCOP, FACCC says.